President Trump announced nine more companies joining TrumpRx, aiming for U.S.-Europe drug price parity using tariffs as leverage. TrumpRx will offer future drug releases at most-favored-nation ...
On the policy front, the U.S. Senate passed the Biosecure Act, legislation designed to limit federal reliance on certain ...
BioMarin’s $4.8 billion all-cash acquisition of Amicus Therapeutics significantly expands its rare disease portfolio with established Fabry and Pompe franchises, adds late-stage pipeline upside, and ...
Atavistik Bio’s $120 million Series B financing bolsters its push to advance first-in-class, allosteric small-molecule therapies for HHT and MPNs, leveraging its AMPS platform to selectively target ...
In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House ...
Lilly’s Attain-Maintain Phase III results show that the oral GLP-1 orforglipron can effectively preserve weight loss after injectable therapy, positioning it as a potential long-term maintenance ...
The Biosecure Act aims to prevent federal funding to Chinese biotech companies labeled "of concern" by the Office of Management and Budget or the Department of Defense. A political shift in the House ...
Novo Nordisk’s NDA filing for CagriSema positions the first fixed-dose amylin–GLP-1 combination as a potential ...
The imminent end of the rebate era means human resources (HR) benefits decision-makers and pharmacy consultants are about to see a paradigm shift. They will need to act quickly to adjust benefits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback